Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.

Previous research has shown that voretigene neparvovec administered subretinally early in childhood for RPE65-mediated ...

ReiThera is proud to announce a new partnership with SillaJen through a comprehensive Master Service Agreement (MSA), which establishes ReiThera as the manufacturing partner for SillaJen’s innovative ...

Cases of secondary tumors have been reported as a possible adverse reaction to the treatment of certain blood cancers with CAR T-cells. A recent analysis of the cases reported to the ...

Abeona Therapeutics Inc.'s promising gene therapy for RDEB, potential FDA approval, undervalued stock, and key risks. Click ...

CAR T-cell therapies have established themselves as a frequently very successful and overall promising treatment option for various blood cancers for which no other effective therapies are available.

The global gene transfer technologies market, valued at US$3.63 billion in 2023, is forecasted to grow at a robust CAGR of 9.7%, reaching US$3.73 ...

We have reached the halfway point of the January transfer window and several sagas are coming to a head. Arsenal and Mikel Arteta are keen to add a new striker this month after Gabriel Jesus was ...

Patients were previously met with fragmented care, limited access to genetic testing and a lack of integrated counselling, OGS clinical director Beau Fenner said. The care was also focused on ...